Our first clinical paper on our lead product BK001
Our first clinical paper on the efficacy of our product in patients suffering from irritable bowel syndrome was published in the World Journal of Gastrointestinal Pharmacology and Therapeutics.
Our first clinical paper on our lead product BK001 (Chitin-Glucan + simethicone) on its efficacy in IBS-patients has been published in the World Journal of Gastrointestinal Pharmacology and Therapeutics. It is generally accepted that rapid action, safety, and tolerability are essential for the development of new IBS therapeutic strategies. The present study showed that BK001 [=GASTRAP® DIRECT] is safe and well tolerated. The study showed a significant and rapid improvement of all quantitative and subjective clinical endpoints (abdominal pain, bloating, flatulence, constipation, diarrhea, and dyschezia) after 2 weeks of BK001 administration.